Tags |
|
|
Links |
|
|
Main Subject - Monitoring And Managing Your Money Manager
Investment performance does not just happen; there must be a process in place to get superior results. There are nearly 15,00
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
0 mutual funds available for you to invest in. How do you decide which one is right for you? Once you select the ones that a
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
e right for you, how do your measure your success? Money mangers are people and they must be monitored and measured; they mus
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
be held responsible for their results. You do not need to pay very much for average fund performance (just invest in indexes
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
.
Above average fund performance does not happen by accident. To get above average fund performance, you must measure and m
Above average fund performance does not happen by accident. To get above average fund performance, you must measure and m
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
onitor. If you are not going to do that, hire someone to do it for you or stick with indexes.Once you select a manager, you
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ust monitor them regularly. Past performance is not only no predictor of the future but, in many cases, the past performance
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
was a result of completely different circumstances and possibly completely different people than those managing your account
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
oday. I would suggest you use the following eight factors:
1.) The mutual fund should be at least three years old. Does a
1.) The mutual fund should be at least three years old. Does a
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
team or one individual manage the fund? How long has the current team manager been running the portfolio?
2.) The fund s
2.) The fund s
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ould have a minimum of $75 million under management
3.) The holdings must be consistent with the style. They should have n
3.) The holdings must be consistent with the style. They should have n
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
more than 20% of the portfolio invested in unrelated assets classes. For Example: A Large Cap Growth product should hold no
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ore than 20% in cash, fixed income and/or international securities.
4.) Correlation to style or peer group: The fund shoul
4.) Correlation to style or peer group: The fund shoul
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
d be highly correlated to the asset class of the investment option. In other words, if they are managing small company stocks
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
make sure that they are actually investing in small stocks.
5.) Make sure the mutual funds investment performance is rela
5.) Make sure the mutual funds investment performance is rela
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ive to the risk they are taking. You can measure a funds risk by using the Alpha and Sharpe ratios.
6.) The funds performa
6.) The funds performa
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ce should be evaluated against its peer group return for the 1,3 and 5 year cumulative return.
7.) The fund expense ratio
7.) The fund expense ratio
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
and fees should not be in the bottom quartile (most expensive).
8.) There should be no perceived organizational problems a
8.) There should be no perceived organizational problems a
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
d the same portfolio management team should be in place for at least two years.Following these eight steps will go a long way
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
in helping you select and monitor a money manager for you. A great resource for this information can be found at Morningstar
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.mainsubjects.org.ua/article/89463/mainsubjects-Monitoring-And-Managing-Your-Money-Manager.html">Monitoring And Managing Your Money Manager</a>
BB link (for phorums):
[url=http://www.mainsubjects.org.ua/article/89463/mainsubjects-Monitoring-And-Managing-Your-Money-Manager.html]Monitoring And Managing Your Money Manager[/url]
Related Articles:
Can Network Marketing Opportunities Pay A Regular Income?
How to Get Rid of Annoying Cold Callers
Why You Need A Bounce Free Email Account For Safelist Marketing
Bookmark it:
|